Pediatric Genetic Fore Genomics Partners with Inocras to Revolutionize Pediatric Genetic Health Screening and Newborn Sequencing
Pediatric Genetic Fore Genomics, a leading provider of pediatric genetic health screening, has announced an exciting new partnership with Inocras, an innovator in whole genome sequencing (WGS) and AI-driven genetic analysis technologies. This collaboration is poised to reshape the landscape of genetic health screening for children and newborns, enhancing early detection, personalized healthcare, and precision medicine for genetic conditions that can affect pediatric populations. The partnership, which will initially roll out in the U.S., is expected to expand to Asian markets in the coming months, further extending the reach of this groundbreaking technology.

The collaboration between Pediatric Genetic Fore Genomics and Inocras will merge Fore’s expertise in pediatric screening services with Inocras’s cutting-edge WGS and bioinformatics platform. This powerful combination will allow healthcare providers and parents to access highly accurate and actionable insights into the genetic health of newborns and children. By identifying potential genetic conditions early, this partnership aims to facilitate timely interventions that can drastically improve health outcomes and overall quality of life for young patients.
This is Pediatric Genetic a significant step forward in the field of genomics and pediatric healthcare, with the potential to change the way genetic conditions are diagnosed and managed in children. The focus on early detection will help clinicians provide tailored medical care from the moment a child is born, providing families with peace of mind and enabling more effective treatment plans.
Advancing Genetic Health Screening with Whole Genome Sequencing
At the heart of this collaboration is Inocras’s state-of-the-art whole genome sequencing platform, which is powered by advanced AI-driven bioinformatics technologies. Whole genome sequencing allows for the analysis of an individual’s entire genetic code, providing unparalleled insight into both rare and common genetic disorders that could affect a child’s health. This technology is capable of identifying a wide array of conditions, from pediatric-onset genetic disorders to those that may not manifest until later in life. By offering whole genome sequencing, Inocras empowers healthcare providers to diagnose conditions early, often before symptoms arise, leading to more proactive and effective medical interventions.
Pediatric Genetic Fore Genomics brings to the table its extensive experience in Pediatric Genetic screening services, which are already trusted by families and healthcare providers. Together with Inocras, Fore is expanding its suite of offerings, providing a comprehensive approach to pediatric healthcare. By combining both companies’ technologies and services, parents and clinicians will have access to comprehensive genetic health assessments for children and newborns, giving them the necessary tools to address potential health concerns at the earliest possible stage.
The partnership will help parents understand their child’s genetic predispositions, providing them with the tools to make informed decisions about their child’s health. Early intervention can significantly improve outcomes for children born with genetic conditions that might otherwise go undiagnosed or misdiagnosed for years. This approach aligns with the growing field of precision medicine, which tailors medical treatments to the individual Pediatric Genetic makeup of each patient, offering more effective treatments and better long-term results.
Access and Convenience: At-Home Sample Collection
One of the most significant challenges for parents when it comes to Pediatric Genetic testing is the complexity and inconvenience of sample collection. Traditional genetic tests often require blood draws or other invasive methods, which can be daunting for families, particularly for newborns and young children. To address this barrier, the partnership between Fore Genomics and Inocras will provide families with a much more accessible and convenient solution.
The newborn sequencing service will offer a provider-ordered test that allows families to easily collect a sample at home using a simple, non-invasive cheek swab. This easy-to-use method removes barriers to testing and makes it more feasible for families, regardless of their geographical location or access to healthcare facilities. This added convenience is expected to encourage wider participation in genetic health screening and ensure that more children receive the benefits of early genetic analysis.
“We are excited to partner with Inocras to bring advanced genetic screening to more families and healthcare providers,” said Matthew Pelo, Founder and CEO of Pediatric Genetic Fore Genomics. “Our shared vision of using genomics to improve health outcomes aligns perfectly with this partnership. Together, we aim to set new standards in pediatric genetic screening to make this service available to all families.”
For Mark Sutherland, Senior Vice President of Business Development at Inocras, the collaboration is an exciting opportunity to showcase the impact of their cutting-edge whole genome sequencing technology. “We are thrilled to partner with Fore Genomics on their pediatric health screening efforts by offering our advanced whole genome sequencing and bioinformatics capabilities,” said Sutherland. “This partnership will showcase the powerful genetic insights our whole genome platform delivers. With this provider-ordered test, families can easily collect a sample at home using a simple cheek swab, making the process more accessible and removing barriers to testing.”
Enhancing Early Diagnosis and Proactive Medical Care
Early diagnosis of pediatric-onset genetic conditions is critical to improving health outcomes. In many cases, children with genetic conditions can experience a better quality of life and more effective treatment when conditions are identified and addressed at an early stage. With the new partnership, Fore Genomics and Inocras aim to provide pediatricians and other healthcare providers with the tools they need to identify potential health issues in newborns and children well before any symptoms might appear.
By providing actionable insights from the results of whole genome sequencing, physicians can quickly develop personalized treatment plans and interventions. This personalized approach is a hallmark of precision medicine, where treatments and health strategies are tailored to the unique genetic profiles of patients. With genetic information, healthcare providers can target therapies that are most likely to be effective for each individual child, avoiding the trial-and-error approach that often comes with more generalized treatments.
The potential for early intervention is particularly crucial in the context of pediatric genetic conditions that can have life-altering consequences if left untreated. For example, certain genetic disorders may result in developmental delays, neurological impairments, or physical disabilities. Early diagnosis through whole genome sequencing allows healthcare providers to intervene sooner, providing children with access to treatments or therapies that could significantly improve their outcomes and quality of life.
In addition to improving health outcomes for children, the partnership will also facilitate greater awareness and education about pediatric genetic conditions. Parents, healthcare providers, and genetic counselors will have the information they need to make informed decisions about genetic testing, diagnosis, and treatment options. This proactive approach to genetic health can help ensure that families have the knowledge they need to make critical healthcare decisions for their children.
A Global Impact: U.S. Rollout and Expansion into Asia
While the initial rollout of the partnership will focus on the U.S. market, both Fore Genomics and Inocras have plans for significant expansion. The potential for global impact is immense, especially in regions like Asia, where access to advanced genetic testing may be limited in some areas. As these technologies become more accessible, the partnership hopes to provide genetic health screening to a larger, more diverse population, improving healthcare outcomes on a global scale.
In particular, the U.S. market presents a prime opportunity for implementing this advanced genetic screening technology due to the country’s strong focus on innovation and healthcare technology. The ability to easily access genetic testing at home will be a significant factor in expanding the reach of this technology across the U.S., allowing for wider adoption of pediatric health screening.
Looking beyond the U.S., both companies are committed to expanding their services to other regions, particularly in Asia. The partnership will work to make genetic health screening more accessible in countries where it might not have been widely available previously, particularly in regions where infant and child health care can benefit from more proactive genetic testing and early interventions.
A Commitment to Innovation and Excellence
The Fore Genomics-Inocras partnership represents a significant step forward in the field of genomic medicine and pediatric healthcare. By combining advanced whole genome sequencing technology with a simple, accessible testing process, the collaboration aims to redefine the landscape of genetic health screening for children and newborns. The ability to offer genetic insights that are both actionable and personalized will enable families to take proactive steps in managing their child’s health, improving both short-term and long-term outcomes.
We are excited to be at the forefront of this innovative partnership, which has the potential to transform how genetic conditions are diagnosed and treated in children,” said Pelo. “Together with Inocras, we are committed to improving health outcomes for children worldwide and providing healthcare providers with the best possible tools to offer personalized, data-driven care.”
Through their commitment to innovation, education, and global accessibility, Fore Genomics and Inocras are setting a new standard in pediatric genetic screening. This partnership promises to open new doors to better health for children everywhere, ultimately paving the way for a future where early diagnosis and personalized treatment options are the norm, not the exception.